UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from D. Boral Capital

UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $25.00 price objective on the stock. D. Bora…

Read Full Article →